Epigenomic subtypes of late-onset Alzheimer's disease reveal distinct microglial signatures.

ABSTRACT: Growing evidence suggests that clinical, pathological, and genetic heterogeneity in late-onset Alzheimer's disease contributes to variable therapeutic outcomes, potentially explaining many trial failures. Advances in molecular subtyping through proteomic and transcriptomic profiling reveal distinct patient subgroups, highlighting disease complexity beyond amyloid-beta plaques and tau tangles. This insight underscores the need to expand molecular subtyping across new molecular layers, to identify novel drug targets for different patient subgroups. In this study, we analyzed genome-wide DNA methylation data from three independent postmortem brain cohorts (n = 831) to identify epigenetic subtypes of late-onset Alzheimer's disease. Unsupervised clustering approaches were employed to identify d

SUBMITTER: Laroche VT 

PROVIDER: S-EPMC11957029 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature